Prudentia Sciences, a Cambridge, MA-based supplier of an AI-powered expertise platform for all times sciences, raised $7M in funding.
The spherical was led by GV, with participation from Iaso Ventures and Advantage.
The corporate intends to make use of the funds to speed up its tempo of product growth and deployment, enhancing its AI-native due diligence platform and increasing its capabilities.
Led by CEO Sadiqa Mahmood, CTO John Reynders, Prudentia Sciences is a expertise firm devoted to accelerating drug pipelines and optimizing return on funding, guaranteeing healthcare improvements attain their scientific growth milestones, affected person influence and full business potential. The platform combines synthetic intelligence with deep scientific experience and superior monetary modeling to handle the complicated challenges of life sciences dealmaking. It presents fast asset diligence and valuation functionality incorporating scientific growth, regulatory and reimbursement issues. The system empowers biopharma firms and buyers to establish crucial dangers, speed up go/no-go choices, and optimize trade-offs swiftly throughout key dimensions similar to time, value, chance of success, and income.
FinSMEs
09/01/2025
